June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Persistence of Subretinal Fluid and the Risk of Enucleation in Group D Retinoblastoma Eyes
Author Affiliations & Notes
  • Grace Shih
    Ophthalmology, University of Southern California, Los Angeles, CA
  • Jesse berry
    Ophthalmology, University of Southern California, Los Angeles, CA
    Ophthalmology, Children's Hospital of Los Angeles, Los Angeles, CA
  • Stavros Moysidis
    Ophthalmology, University of Southern California, Los Angeles, CA
  • A. Linn Murphree
    Ophthalmology, Children's Hospital of Los Angeles, Los Angeles, CA
  • Rima Jubran
    Ophthalmology, Children's Hospital of Los Angeles, Los Angeles, CA
  • Jonathan W Kim
    Ophthalmology, University of Southern California, Los Angeles, CA
    Ophthalmology, Children's Hospital of Los Angeles, Los Angeles, CA
  • Footnotes
    Commercial Relationships Grace Shih, None; Jesse berry, None; Stavros Moysidis, None; A. Murphree, None; Rima Jubran, None; Jonathan Kim, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 6057. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Grace Shih, Jesse berry, Stavros Moysidis, A. Linn Murphree, Rima Jubran, Jonathan W Kim; Persistence of Subretinal Fluid and the Risk of Enucleation in Group D Retinoblastoma Eyes. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):6057.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the association of persistent subretinal fluid (SRF) and the need for enucleation in Group D eyes of bilateral retinoblastoma treated with chemoreduction.

Methods: 53 Group D eyes were evaluated for the presence of SRF at diagnosis. They were subsequently treated with primary chemoreduction, using a 3 drug chemotherapy regimen. Globe survival analysis was used to evaluate whether persistence of subretinal fluid was associated with persistent tumor activity after chemoreduction and a worse overall outcome (i.e. enucleation). Logistic regression analysis was used to assess the association between duration of SRF and risk for enucleation.

Results: 79.25% (n=42) of Group D eyes exhibited SRF at diagnosis. Of these 42 eyes, 25 eyes showed subretinal fluid that persisted after the first round of chemotherapy. 9 eyes demonstrated continued SRF after 3 cycles of chemotherapy and 2 eyes continued with fluid at 6 months. Ten eyes ultimately required enucleation (10/53 or 18.9%). Only one of the 10 enucleated eyes demonstrated persistent SRF at the time of enucleation. 8 of 10 eyes contained histologic evidence of viable tumor cells. There was no statistically significant association between the persistence of SRF and risk for enucleation.

Conclusions: We hypothesized that the persistence of subretinal fluid during chemotherapy was a risk factor for enucleation. However, the duration of SRF was not found to be an independent predictor of whether Group D eyes will ultimately require enucleation following chemoreduction.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×